Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18435053 | 0.81 | SHBG (0.43) | SHBG | |
| SCHEMBL12424437 | 0.79 | SHBG (0.52) | SHBGLMNACYP2C9DPP4DPP7 | |
| SCHEMBL17198162 | 0.79 | SHBG (0.52) | SHBGLMNACYP2C9DPP4DPP7 | |
| SCHEMBL4843035 | 0.79 | SHBG (0.52) | SHBGLMNACYP2C9DPP4DPP7 | |
| SCHEMBL18862407 | 0.76 | SHBG (0.43) | SHBG | |
| SCHEMBL910914 | 0.76 | — | — | |
| Water SCHEMBL10629881 | 0.73 | — | — | |
| SCHEMBL18685378 | 0.73 | SHBG (0.34) | SHBG | |
| SCHEMBL4888692 | 0.72 | SHBG (0.42) | SHBGLMNACYP2C9DPP4DPP7 | |
| SCHEMBL6757996 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040992-A1 | OLIGOOXOPIPERAZINES AND METHODS OF MAKING AND USING THEM | NEW YORK UNIVERSITY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040992-A1 | OLIGOOXOPIPERAZINES AND METHODS OF MAKING AND USING THEM | THOP1, NPY5R, DHPS | SHBG 855/4885LMNA 3438/4885CYP2C9 3599/4885 |
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | HDAC10, PDE10A, PDE9A | SHBG 1281/4885LMNA 3945/4885CYP2C9 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.